Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

537.50
-9.8600-1.80%
Volume:591.67K
Turnover:318.01M
Market Cap:58.03B
PE:13.63
High:547.59
Open:546.50
Low:532.75
Close:547.36
Loading ...

Regeneron (REGN) Gets a Hold from RBC Capital

TIPRANKS
·
1 hour ago

RBC Raises Price Target on Regeneron Pharmaceuticals to $688 From $662, Keeps Sector Perform Rating

MT Newswires Live
·
Yesterday

BUZZ-Apogee Therapeutics jumps after eczema drug meets main goal in mid-stage study

Reuters
·
Yesterday

TD Cowen Remains a Buy on Regeneron (REGN)

TIPRANKS
·
03 Jul

Regeneron (REGN) Receives a Buy from Citi

TIPRANKS
·
03 Jul

BUZZ-U.S. STOCKS ON THE MOVE-Investar, Steel Dynamics, Axos Financial

Reuters
·
03 Jul

BRIEF-Regeneron Says Wholesale Acquisition Cost For Lynozyfic Is $470.00 Per 5 Mg Vial

Reuters
·
03 Jul

Regeneron Pharmaceuticals- Wholesale Acquisition Cost for Lynozyfic Is $470.00 per 5 Mg Vial, $18,800.00 per 200 Mg Vial

THOMSON REUTERS
·
03 Jul

Shares of Regeneron Pharmaceuticals up 2.8% at $550.06 After Blood Cancer Therapy Gets Accelerated FDA Approval

THOMSON REUTERS
·
02 Jul

US FDA approves Regeneron's blood cancer therapy

Reuters
·
02 Jul

Regeneron Pharmaceuticals Secures FDA Accelerated Approval for Lynozyfic™ in Treating Relapsed or Refractory Multiple Myeloma

Reuters
·
02 Jul

Lynozyfic™ (Linvoseltamab-Gcpt) Receives FDA Accelerated Approval for Treatment of Relapsed or Refractory Multiple Myeloma

THOMSON REUTERS
·
02 Jul

Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
02 Jul

Argus Research Downgrades Regeneron Pharmaceuticals to Hold From Buy

MT Newswires Live
·
30 Jun

Bayer AG's Eylea™ 8 mg Receives EU Approval for Extended 6-Month Treatment Intervals in Retinal Diseases

Reuters
·
27 Jun

Regeneron Pharmaceuticals Inc. to Announce Second Quarter 2025 Financial and Operating Results

Reuters
·
27 Jun

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
25 Jun

Sanofi SA Announces Breakthrough Results: Dupixent Outperforms Xolair in Phase 4 Study for Chronic Rhinosinusitis with Nasal Polyps and Asthma

Reuters
·
24 Jun

Regeneron announces donation matching program with Good Days

TIPRANKS
·
24 Jun

Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says

Reuters
·
21 Jun